Drugs / MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC
MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00203879 | Feb 2002 → May 2006 | metastatic melanoma | University of Chicago | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00203879 ↗ |
| Route | Subcutaneous | “Approximately 120 x 106 pulsed cells will be injected subcutaneously at a site near a lymph node not thought to be involved with tumor.” NCT00203879 ↗ |